Sutro Biopharma Inc (NASDAQ:STRO) – Stock analysts at Piper Jaffray Companies issued their Q1 2020 earnings per share estimates for shares of Sutro Biopharma in a research report issued on Monday, April 1st, according to Zacks Investment Research. Piper Jaffray Companies analyst E. Tenthoff forecasts that the company will earn ($0.72) per share for the quarter. Piper Jaffray Companies also issued estimates for Sutro Biopharma’s Q2 2020 earnings at ($0.71) EPS, Q3 2020 earnings at ($0.83) EPS and Q4 2020 earnings at ($0.99) EPS.
STRO has been the subject of a number of other research reports. Zacks Investment Research downgraded Sutro Biopharma from a “hold” rating to a “sell” rating in a research report on Thursday, January 17th. Wedbush boosted their price target on Sutro Biopharma from $20.00 to $22.00 and gave the company an “outperform” rating in a research report on Monday, March 4th. Finally, ValuEngine downgraded Sutro Biopharma from a “buy” rating to a “hold” rating in a research report on Thursday, January 24th. One equities research analyst has rated the stock with a sell rating and five have given a buy rating to the company. Sutro Biopharma presently has a consensus rating of “Buy” and an average target price of $24.33.
Hedge funds and other institutional investors have recently modified their holdings of the company. American International Group Inc. purchased a new stake in shares of Sutro Biopharma in the fourth quarter worth about $38,000. Deutsche Bank AG purchased a new stake in shares of Sutro Biopharma in the fourth quarter worth about $87,000. SG Americas Securities LLC purchased a new stake in shares of Sutro Biopharma in the fourth quarter worth about $169,000. Alpine Global Management LLC purchased a new stake in shares of Sutro Biopharma in the third quarter worth about $375,000. Finally, Geode Capital Management LLC purchased a new stake in shares of Sutro Biopharma in the fourth quarter worth about $456,000. 47.34% of the stock is owned by institutional investors.
About Sutro Biopharma
Sutro Biopharma, Inc operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis platform, XpressCF. The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for multiple myeloma and non-Hodgkin lymphoma; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers.
Featured Article: What is Call Option Volume?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Sutro Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sutro Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.